PURPOSE: A composition for treating Epstein-Barr virus-positive gastric cancer is provided to suppress proliferation of Epstein-Barr virus and to effectively treat Epstein-Barr virus-positive gastric cancer when ganciclovir and gemcitabine are combined. CONSTITUTION: A pharmaceutical composition for treating Epstein-Barr virus-positive gastric cancer contains an anti-herpes viral agent and 1 ng/ml or greater of gemcitabine. The anti-herpes viral agent is selected among ganciclovir, acyclovir, penciclovir, vidarabine, idoxuridine, trifluridine, edoxudine, brivudin, and cytarabine. The pharmaceutical composition contains 160 ng/ml of gemcitabine. A method for inducing lytic infection of Epstein-Barr virus comprises the step of administering at least 1 ng/mg of gemcitabine to a subject.본 발명은 간시클로비르 및 젬시타빈을 포함하는 EBV 양성 위암 치료용 조성물에 관한 것으로, EBV 양성 위암 세포에 간시클로비르를 단독으로 사용할 때에 비하여 젬시타빈을 병용투여할 때, EBV 바이러스에 대한 증식 억제 효과가 뛰어나, EBV 양성 위암을 치료하는 데에 효과적으로 이용가능 하다.
